Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05590143 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2

Study acronym: MERCURI-2
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Aug 2025 to May 14, 2025
    • Study completion date: Oct 2025 to Sep 2025
    • Site details revised at 6 of 6 sites
    v4
  2. Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) to Amsterdam UMCv3 Show 4 more changesShow less
    • Primary completion date: Nov 2025 to Aug 2025
    • Study completion date: Dec 2025 to Oct 2025
    • Secondary endpoints: 21 to 22
    • Study description expanded, about 11 words
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2023 to Jun 9, 2023
    • Site details revised at 6 of 6 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multi-centre, triple-blinded (patients, physicians, investigators), parallel-group, balanced (1:1), stratified (sex, type 2 diabetes mellitus), randomized, controlled (placebo), phase IV clinical trial to investigate the potential of preoperative initiation (from day 1 before surgery) and perioperative continuation (until day 2 after surgery) of the SGLT2 inhibitor dapagliflozin 10 mg once daily to prevent AKI according to the KDIGO criteria (an increase in serum creatinine by 0.3 mg/dl (26.5 mmol/l) within 48 hours; or an increase in serum creatinine to 1.5 times baseline, within 7 days; or a urine output \<0.5 ml/kg/h for \>6 hours) in adult (\>18 years old) patients undergoing cardiopulmonary bypass surgery.
Trial Details
NCT Number NCT05590143
Lead Sponsor Amsterdam UMC
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Conditions
(from sponsor)		 Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor
Related terms Acute Kidney Injury
Enrollment 784 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov